SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
DaveAu
rkrw
To: tuck who wrote (50577)12/21/2018 5:24:35 PM
From: Biomaven2 Recommendations  Read Replies (1) of 52153
 
As I responded on twitter, it's always possible that an AE like cardiomyopathy shows up in a big study, but it likely would not impact MACE over the period of this trial.

There are two aspects to roxa safety that are worth noting. First, the dose is very low - they are barely tickling the HIF system, producing the same sort of response that happens if you move to a high altitude. Second, the intermittent HIF activation because of their dosing strategy serves to differentiate from the sort of study you cite.

EPO causes MACE events, and that really is the only reason roxa is under suspicion in the first place. Pretty much all the acute effects like on hypertension and on cholesterol are favorable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News